Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS )

33.32 +0.11 (+0.33%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 437,759
Open 33.21
Bid (Size) 32.31 (5)
Ask (Size) 33.50 (1)
Prev. Close 33.21
Today's Range 32.50 - 33.39
52wk Range 24.34 - 73.80
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga

Performance

YTD
-45.62%
-45.62%
1 Month
+4.42%
+4.42%
3 Month
+8.36%
+8.36%
6 Month
-17.52%
-17.52%
1 Year
-44.56%
-44.56%

More News

Read More
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
Via Benzinga
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Via Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
Via Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Via The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
Via Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Via The Motley Fool
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Via Benzinga
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.